Νεμπιβολόλη (Greek Wikipedia)

Analysis of information sources in references of the Wikipedia article "Νεμπιβολόλη" in Greek language version.

refsWebsite

Global rank Greek rank

16nih.gov

4^th place

14doi.org

2^nd place

3^rd place

3web.archive.org

1^st place

2drugs.com

399^th place

130^th place

2clincalc.com

3,912^th place

594^th place

2archive.org

6^th place

5^th place

1books.google.com

3^rd place

6^th place

1medicaid.gov

low place

9,694^th place

1frx.com

low place

9,801^st place

1worldcat.org

5^th place

8^th place

1adisonline.com

low place

adisonline.com

Baldwin CM, Keam SJ. Nebivolol: In the Treatment of Hypertension in the US. Am J Cardiovasc Drugs 2009; 9 (4): 253–260. Link text Αρχειοθετήθηκε 8 October 2011 στο Wayback Machine.

archive.org

«Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma». Pharmacotherapy 19 (8): 974–8. August 1999. doi:10.1592/phco.19.11.974.31575. PMID 10453968. https://archive.org/details/sim_pharmacotherapy_1999-08_19_8/page/974.
«A comparison of the beta1-selectivity of three beta1-selective beta-blockers». J Clin Pharm Ther 28 (3): 179–86. June 2003. doi:10.1046/j.1365-2710.2003.00477.x. PMID 12795776. https://archive.org/details/sim_journal-of-clinical-pharmacy-and-therapeutics_2003-06_28_3/page/179.

books.google.com

Fischer, Jnos· Ganellin, C. Robin (2006). Analogue-based Drug Discovery (στα Αγγλικά). John Wiley & Sons. σελ. 462. ISBN 9783527607495.

clincalc.com

«The Top 300 of 2020». ClinCalc. Ανακτήθηκε στις 11 Απριλίου 2020.
«Nebivolol Hydrochloride - Drug Usage Statistics». ClinCalc. Αρχειοθετήθηκε από το πρωτότυπο στις 13 Ιανουαρίου 2021. Ανακτήθηκε στις 11 Απριλίου 2020.

doi.org

dx.doi.org

«Nebivolol: third-generation beta-blockade». Expert Opin Pharmacother 8 (10): 1539–50. July 2007. doi:10.1517/14656566.8.10.1539. PMID 17661735.
«Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma». Pharmacotherapy 19 (8): 974–8. August 1999. doi:10.1592/phco.19.11.974.31575. PMID 10453968. https://archive.org/details/sim_pharmacotherapy_1999-08_19_8/page/974.
«Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies». Eur. J. Pharmacol. 460 (1): 19–26. January 2003. doi:10.1016/S0014-2999(02)02875-3. PMID 12535855.
«A comparison of the beta1-selectivity of three beta1-selective beta-blockers». J Clin Pharm Ther 28 (3): 179–86. June 2003. doi:10.1046/j.1365-2710.2003.00477.x. PMID 12795776. https://archive.org/details/sim_journal-of-clinical-pharmacy-and-therapeutics_2003-06_28_3/page/179.
Gheldiu, Ana-Maria; Vlase, Laurian; Popa, Adina; Briciu, Corina; Muntean, Dana; Bocsan, Corina; Buzoianu, Anca; Achim, Marcela και άλλοι. (2017). «Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers». Journal of Pharmacy & Pharmaceutical Sciences 20: 68–80. doi:10.18433/J3B61H. ISSN 1482-1826. PMID 28459657.
«Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics». Drugs 67 (8): 1097–107. 2007. doi:10.2165/00003495-200767080-00001. PMID 17521213.
Galougahi, Keyvan (19 February 2016). «β3 Adrenergic Stimulation Restores Nitric Oxide/Redox Balance and Enhances Endothelial Function in Hyperglycemia». Journal of the American Heart Association 5 (2): e002824. doi:10.1161/JAHA.115.002824. PMID 26896479.
Weiss R (2006). «Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation». Vasc Health Risk Manag 2 (3): 303–8. doi:10.2147/vhrm.2006.2.3.303. PMID 17326335.
Bakris G (May 2009). «An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade». J. Cardiovasc. Pharmacol. 53 (5): 379–87. doi:10.1097/FJC.0b013e31819fd501. PMID 19454898.
«Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension». Am. J. Cardiol. 92 (3): 344–8. August 2003. doi:10.1016/S0002-9149(03)00645-3. PMID 12888152.
«Nebivolol: a review of its clinical and pharmacological characteristics». Int J Clin Pharmacol Ther 44 (8): 344–57. August 2006. doi:10.5414/cpp44344. PMID 16961165.
Pessina AC (December 2001). «Metabolic effects and safety profile of nebivolol». J. Cardiovasc. Pharmacol.. 38 Suppl 3: S33–5. doi:10.1097/00005344-200112003-00006. PMID 11811391.
Weber MA (December 2005). «The role of the new beta-blockers in treating cardiovascular disease». Am. J. Hypertens. 18 (12 Pt 2): 169S–176S. doi:10.1016/j.amjhyper.2005.09.009. PMID 16373195.
«Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients». J. Hypertens. 19 (8): 1429–35. August 2001. doi:10.1097/00004872-200108000-00011. PMID 11518851.

drugs.com

«Nebivolol Hydrochloride Monograph for Professionals». Drugs.com. American Society of Health-System Pharmacists. Ανακτήθηκε στις 3 Μαρτίου 2019.
«Nebivolol Pregnancy and Breastfeeding Warnings». Drugs.com. Ανακτήθηκε στις 3 Μαρτίου 2019.

frx.com

«Prescribing information for Bystolic» (PDF). Ανακτήθηκε στις 11 Ιουνίου 2009.

medicaid.gov

data.medicaid.gov

«NADAC as of 2019-02-27». Centers for Medicare and Medicaid Services. Αρχειοθετήθηκε από το πρωτότυπο στις 6 Μαρτίου 2019. Ανακτήθηκε στις 3 Μαρτίου 2019.

nih.gov

ncbi.nlm.nih.gov

«Nebivolol: third-generation beta-blockade». Expert Opin Pharmacother 8 (10): 1539–50. July 2007. doi:10.1517/14656566.8.10.1539. PMID 17661735.
«Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma». Pharmacotherapy 19 (8): 974–8. August 1999. doi:10.1592/phco.19.11.974.31575. PMID 10453968. https://archive.org/details/sim_pharmacotherapy_1999-08_19_8/page/974.
«Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies». Eur. J. Pharmacol. 460 (1): 19–26. January 2003. doi:10.1016/S0014-2999(02)02875-3. PMID 12535855.
«A comparison of the beta1-selectivity of three beta1-selective beta-blockers». J Clin Pharm Ther 28 (3): 179–86. June 2003. doi:10.1046/j.1365-2710.2003.00477.x. PMID 12795776. https://archive.org/details/sim_journal-of-clinical-pharmacy-and-therapeutics_2003-06_28_3/page/179.
Gheldiu, Ana-Maria; Vlase, Laurian; Popa, Adina; Briciu, Corina; Muntean, Dana; Bocsan, Corina; Buzoianu, Anca; Achim, Marcela και άλλοι. (2017). «Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers». Journal of Pharmacy & Pharmaceutical Sciences 20: 68–80. doi:10.18433/J3B61H. ISSN 1482-1826. PMID 28459657.
«Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics». Drugs 67 (8): 1097–107. 2007. doi:10.2165/00003495-200767080-00001. PMID 17521213.
Galougahi, Keyvan (19 February 2016). «β3 Adrenergic Stimulation Restores Nitric Oxide/Redox Balance and Enhances Endothelial Function in Hyperglycemia». Journal of the American Heart Association 5 (2): e002824. doi:10.1161/JAHA.115.002824. PMID 26896479.
Weiss R (2006). «Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation». Vasc Health Risk Manag 2 (3): 303–8. doi:10.2147/vhrm.2006.2.3.303. PMID 17326335.
Bakris G (May 2009). «An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade». J. Cardiovasc. Pharmacol. 53 (5): 379–87. doi:10.1097/FJC.0b013e31819fd501. PMID 19454898.
«Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension». Am. J. Cardiol. 92 (3): 344–8. August 2003. doi:10.1016/S0002-9149(03)00645-3. PMID 12888152.
«Nebivolol: a review of its clinical and pharmacological characteristics». Int J Clin Pharmacol Ther 44 (8): 344–57. August 2006. doi:10.5414/cpp44344. PMID 16961165.
Pessina AC (December 2001). «Metabolic effects and safety profile of nebivolol». J. Cardiovasc. Pharmacol.. 38 Suppl 3: S33–5. doi:10.1097/00005344-200112003-00006. PMID 11811391.
Weber MA (December 2005). «The role of the new beta-blockers in treating cardiovascular disease». Am. J. Hypertens. 18 (12 Pt 2): 169S–176S. doi:10.1016/j.amjhyper.2005.09.009. PMID 16373195.
«Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients». J. Hypertens. 19 (8): 1429–35. August 2001. doi:10.1097/00004872-200108000-00011. PMID 11518851.

pubmedcentral.nih.gov

Galougahi, Keyvan (19 February 2016). «β3 Adrenergic Stimulation Restores Nitric Oxide/Redox Balance and Enhances Endothelial Function in Hyperglycemia». Journal of the American Heart Association 5 (2): e002824. doi:10.1161/JAHA.115.002824. PMID 26896479.
Weiss R (2006). «Nebivolol: a novel beta-blocker with nitric oxide-induced vasodilatation». Vasc Health Risk Manag 2 (3): 303–8. doi:10.2147/vhrm.2006.2.3.303. PMID 17326335.

web.archive.org

«NADAC as of 2019-02-27». Centers for Medicare and Medicaid Services. Αρχειοθετήθηκε από το πρωτότυπο στις 6 Μαρτίου 2019. Ανακτήθηκε στις 3 Μαρτίου 2019.
«Nebivolol Hydrochloride - Drug Usage Statistics». ClinCalc. Αρχειοθετήθηκε από το πρωτότυπο στις 13 Ιανουαρίου 2021. Ανακτήθηκε στις 11 Απριλίου 2020.
Baldwin CM, Keam SJ. Nebivolol: In the Treatment of Hypertension in the US. Am J Cardiovasc Drugs 2009; 9 (4): 253–260. Link text Αρχειοθετήθηκε 8 October 2011 στο Wayback Machine.

worldcat.org

Gheldiu, Ana-Maria; Vlase, Laurian; Popa, Adina; Briciu, Corina; Muntean, Dana; Bocsan, Corina; Buzoianu, Anca; Achim, Marcela και άλλοι. (2017). «Investigation of a Potential Pharmacokinetic Interaction Between Nebivolol and Fluvoxamine in Healthy Volunteers». Journal of Pharmacy & Pharmaceutical Sciences 20: 68–80. doi:10.18433/J3B61H. ISSN 1482-1826. PMID 28459657.